文献速递头颈外科

聚焦于不平等的症状变化的人乳头状瘤病毒相关口咽癌随访(FOCUS):前瞻性患者报告结局采集

Follow-up for human papillomavirus-related oropharynx cancer concentrated on unequal symptom change (FOCUS): Prospective patient-reported outcome collection.
PubMed 文献 · Head Neck · 2024-04-29

该前瞻性注册研究纳入p16+口咽癌患者,将电子患者报告结局(ePRO)和循环肿瘤DNA(ctDNA)纳入常规监测,评估可行性及检测复发的效能。结果显示ePRO月报依从性未达预设的85%阈值(44/76,58%),主要受邮件接收技术困难限制;ePRO联合ctDNA检测复发的敏感性为75%。

要点

  • ePRO月报依从性为58%,未达到预设的≥85%合格阈值。
  • ePRO联合ctDNA检测复发的敏感性为75%。
  • 医护人员反馈与ePRO依从性升高显著相关。

核心结论

  • 尽管ePRO的依从性低于预期,研究结果提示将HPV ctDNA纳入HPV相关口咽癌的监测模式具有前景,并提出了优化ePRO形式以实现个性化监测的方法建议。

研究设计与样本

  • 前瞻性注册研究,纳入接受治疗的口咽癌患者,将ePRO和ctDNA纳入常规监测。
  • ePRO每月通过电子邮件发送,持续1年;血液HPV ctDNA检测每3-6个月进行一次。
  • 主要目标为评估患者对基于ePRO监测的依从性,合格依从性定义为≥85%的患者完成每月ePRO。

主要发现

  • 122例患者最初表示有兴趣,76例完成电子知情同意流程,其中44/76(58%)在1年内对每月调查依从;因此未达到合格依从性。
  • 与通过电子邮件接收ePRO相关的技术困难在很大程度上限制了参与。
  • 医护人员反馈与ePRO依从性升高显著相关。
  • 106例患者接受了ctDNA检测,平均每例患者检测3次。
  • ePRO联合ctDNA检测复发的敏感性为75%。

关键数值与推荐

  • 合格依从性定义为≥85%的患者完成每月ePRO。
  • ePRO每月通过电子邮件发送,持续1年。
  • 血液HPV ctDNA检测每3-6个月进行一次。
  • ePRO联合ctDNA检测复发的敏感性为75%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 与通过电子邮件接收ePRO相关的技术困难在很大程度上限制了参与。
  • ePRO的依从性低于预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-treatment surveillance recommendations for oropharyngeal cancer do not vary with p16 status despite the differences in outcomes. The optimal algorithm personalizing follow-up for these patients remains undefined. Here, we evaluate the feasibility and utility of incorporating electronic patient-reported outcomes (ePROs) and circulating tumor DNA (ctDNA) into routine surveillance for patients treated for p16+ oropharynx cancer. METHODS: A prospective registry was developed in which ePROs and ctDNA were incorporated into routine surveillance among patients with oropharynx cancer. ePROs were emailed monthly for 1 year and blood HPV ctDNA testing was performed every 3-6 months. The primary objective was to assess patient compliance with ePRO-based surveillance with adequate compliance defined as ≥85% of patients completing monthly ePROs. Sensitivity, specificity, and positive/negative predictive values to detect recurrence were calculated for ePROs, HPV ctDNA, or the combination. RESULTS: Of 122 patients who initially expressed interest, 76 completed the electronic consent process and 44/76 (58%) were compliant with monthly surveys over 1 year; thus adequate compliance was not achieved. Technical difficulties associated with ePRO receipt through email largely limited participation. Provider feedback was significantly associated with heightened ePRO compliance. One hundred and six patients had ctDNA testing with a mean number of three tests per patient. Sensitivity to detect recurrence was 75% for the combination of ePROs and ctDNA. CONCLUSION: Despite lower than anticipated compliance with ePROs, our findings show promise for incorporation of HPV ctDNA into surveillance paradigms for HPV-related oropharynx cancer with suggestions of methods to optimize ePRO formats for personalized surveillance.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Edwards DM, Gharzai LA, Wang W, et al. Follow-up for human papillomavirus-related oropharynx cancer concentrated on unequal symptom change (FOCUS): Prospective patient-reported outcome collection. Head Neck. 2024. PMID: 38680087. doi:10.1002/hed.27778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。